Atorvastatin and Endothelial Progenitor Cells in Heart Procedures
Author Information
Author(s): Hibbert Benjamin, Ma Xiaoli, Pourdjabbar Ali, Simard Trevor, Rayner Katey, Sun Jiangfeng, Chen Yong-Xiang, Filion Lionel, O'Brien Edward R.
Primary Institution: University of Ottawa Heart Institute
Hypothesis
High dose Atorvastatin therapy initiated prior to PCI mobilizes EPCs that may be capable of enhancing arterial repair.
Conclusion
High dose Atorvastatin therapy pre-PCI improves EPC number and function in humans, which may explain the clinical benefits seen in patients undergoing coronary interventions.
Supporting Evidence
- EPC levels increased 3.5-fold with Atorvastatin treatment before PCI.
- CAC levels also rose significantly with Atorvastatin therapy.
- The study included a control group receiving standard therapy for comparison.
Takeaway
This study found that giving patients a high dose of Atorvastatin before heart procedures helps their body produce more special cells that help heal blood vessels.
Methodology
Patients were randomized to receive either Atorvastatin or standard therapy before undergoing PCI, and EPCs were measured using flow cytometry.
Potential Biases
Recruitment of statin-naïve patients was challenging due to the common use of statins in the population.
Limitations
The study had a small sample size and was limited to male patients, which may affect the generalizability of the results.
Participant Demographics
All participants were male patients undergoing PCI, aged 59.5 to 63 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website